^^^^^ Paxlovid is the way to go for prevention. Efficient, just some pills to take.
Remdesivir is not making a consensus in being effective for mild symptoms situation.
Even for hospitalized patients. The benefits of remdesivir in the treatment of hospitalized patients with COVID-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use.
There are other issues with remdesivir. Made by the US company Gilead, is extremely expensive and has to be given intravenously. The guideline, published in the British Medical Journal, concluded that “most patients would not prefer intravenous treatment with remdesivir given the low certainty evidence. Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains.”
www.theguardian.com
Conclusions: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.
Source:
pubmed.ncbi.nlm.nih.gov
Remdesivir is not making a consensus in being effective for mild symptoms situation.
Even for hospitalized patients. The benefits of remdesivir in the treatment of hospitalized patients with COVID-19 remain debated with the National Institutes of Health and the World Health Organization providing contradictory recommendations for and against use.
There are other issues with remdesivir. Made by the US company Gilead, is extremely expensive and has to be given intravenously. The guideline, published in the British Medical Journal, concluded that “most patients would not prefer intravenous treatment with remdesivir given the low certainty evidence. Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains.”
Remdesivir: don't use drug Trump took for Covid-19, WHO says
Agency says no evidence the intravenous antiviral works for severe infections
Conclusions: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.
Source:
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis, May 2022
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis - PubMed
Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.




